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The majority of patients with pancreatic cancer present with
advanced disease. Only 10% of patients have potentially operable
tumours confined to the pancreas, but, even then, most relapse
following surgical intervention. Presenting features include ob-
structive jaundice, weight loss, lumbar or epigastric pain,
dyspepsia, recurrent attacks of pancreatitis and ascites. Para-
neoplastic phenomena may occur and a hypercoagulable state may
cause thrombotic complications, such as deep vein thrombosis or
thrombophlebitis migrans. Smoking and chronic pancreatitis are
known risk factors. The relative risk of pancreatic cancer is
increased in certain rare familial syndromes, such as Peutz–Jegers
syndrome, familial atypical multiple mole melanoma syndrome
and hereditary pancreatitis (The European Pancreatic Cancer
Research Cooperative (EPCRC, 2004)).
Endoscopic ultrasound (EUS) was introduced in the early 1980s
and has assumed a central role in the detection and characterisa-
tion of pancreatic tumours. It is particularly sensitive for small
tumours and for the assessment of lymph node involvement
(Rosch et al, 1992). Within the last 10 years, the establishment of
EUS guided fine needle aspiration and lymph node sampling has
provided a convenient means by which to establish a cytological
diagnosis (Chen and Eloubeidi, 2004). Improvements in CT
scanning in the 1990s with the development of multiphase thin
slice helical CT have enhanced the sensitivity of CT for tumours
less than 2cm (Zeman et al, 1997). In practice, CT and EUS will be
performed as complementary staging investigations.
18F-deoxyglu-
cose-positron emission tomography (FDG-PET), PET-CT and MRI
are useful adjuncts with the former particularly useful for the
detection of occult metastatic disease. Together, these imaging
modalities aim to establish a diagnosis and determine suitability of
surgery. Although the detection of operable candidates may
improve survival for that group, more accurate imaging is likely
to increase the number of patients deemed unresectable and is
therefore unlikely to have significantly impacted on survival trends
in pancreatic cancer.
In the advanced disease setting, the major therapeutic advance
has been the establishment of single agent gemcitabine as a
standard of care. This is based on the results of a single
randomised clinical trial in 1997 comparing gemcitabine with
bolus 5-fluorouracil (5-FU). This demonstrated improved clinical
benefit response rates (24 vs 5%; P¼0.0022), median survival
duration (5.65 vs 4.4 months; P¼0.0025) 1-year survival (19 vs 2%)
in favour of gemcitabine (Burris III et al, 1997). On the basis of
these data, gemcitabine became widely adopted as a first-line
palliative therapy in pancreatic cancer following NICE guidance in
May 2001, although there may have been some utilisation of this
agent before this. The impact of gemcitabine on survival is
therefore unlikely to be apparent in the period in question,
although the survival benefit for gemcitabine is at best modest.
Surgical resection is offered to a minority of patients. Since 1980
there have been considerable improvements in perioperative
morbidity and mortality brought about through advances in surgical
techniques, perioperative care and diagnostic imaging. The
concentration of surgery within specialist centres with a high
volume of cases has also contributed to improved surgical outcomes
(Andren-Sandberg and Neoptolemos, 2002). This may not be clearly
reflected in the overall survival trends as patients with resectable
disease represent a small cohort of the overall pancreatic cancer
population. Adjuvant chemotherapy has been developed recently. In
the ESPAC-1 trial of observation, chemotherapy (bolus 5-FU) and
chemoradiotherapy in 549 patients with resected pancreatic cancer,
there was an improvement in survival for the chemotherapy but not
the chemoradiotherapy arms. The trial was first reported in 2001
with mature data presented in 2004 (Neoptolemos et al, 2001;
Neoptolemos et al, 2004). A meta-analysis of five adjuvant trials in
pancreatic cancer supports the use of adjuvant chemotherapy
(Stocken et al, 2005). The ongoing phase III ESPAC-3 trial is
comparing gemcitabine vs bolus 5-FU in the adjuvant setting.
Adjuvant therapy would not have influenced survival trends during
the period of review, but based on current evidence, many patients
now routinely receive postoperative chemotherapy. The integration
of radiation therapy incorporating newer techniques for delivery
and tumour targeting is currently an expanding area of investigation
for patients with both operable and locally advanced disease and for
the latter may offer the scope for conversion to resectable disease.
On the basis of the analysis presented, 5-year survival rates have
not changed significantly between 1986–1990 and 1996–1999 as
might have been predicted from earlier discussion. There have
been small improvements in the 1-year survival for both men and
women. The improvements in diagnostic imaging and reduction
in surgical morbidity/mortality may have contributed to this,
although patients with advanced disease would have accounted for
the majority of cases. Depending on the uptake of first-line
gemcitabine, palliative chemotherapy may account for some of the
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through multidisciplinary team meetings established in the late
1990s, may have improved access to relevant services and also
impacted on survival trends. The changes in survival among the
various deprivation categories have been similarly minimal with a
reported slight increase in the deprivation gap in men relative to
women at 1 and 5 years.
The survival trends presented are reflective of the aggressive
nature of pancreatic cancer. Earlier diagnosis and new therapeutic
advances are clearly required to improve this situation. In
advanced disease, the routine use of gemcitabine first-line may
result in improved survival in the next period of analysis but the
magnitude is unlikely to be large. However, for patients fit for
therapy, gemcitabine remains a widely used standard of care
following several recent negative randomised controlled trials of
combination chemotherapy regimens vs gemcitabine monother-
apy. In a recent meta-analysis a survival benefit was demonstrated
for gemcitabine doublets incorporating capecitabine or platinums
and this may impact on future practice (Sultana et al, 2007).
Significant resources have been applied to elucidating the
pathophysiological mechanisms of pancreatic cancer including the
role of tumour suppressor and promoter genes and key tumorigenic
pathways. Erlotinib, a targeted therapy against the epidermal growth
factor pathway (EGFR), has recently been shown in a randomised
phase III trial to be superior to gemcitabine alone, again with a
modest survival gain (Moore et al,2 0 0 7 ) .H o w e v e r ,p r e l i m i n a r y
reports of randomised trials of other biological therapies combined
in gemcitabine doublets (cetuximab, targeting the EGFR pathway
and bevacizumab, targeting the vascular endothelial growth factor
axis) have disappointingly not indicated improvement in survival
for combination therapy (Kindler et al, 2007; Philip et al,2 0 0 7 ) .T o
make progress, the impetus therefore remains strong for the
continued conduct of high quality preclinical and translational
research incorporating newer technologies directed at systems
biology, in tandem with the development and evaluation of other
rational targeted therapies including the multi-targeted small
molecule receptor tyrosine kinase inhibitors and vaccine therapy,
likely to be as part of combinatorial therapy.
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